VolitionRX Limited (NYSEAMERICAN:VNRX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of VolitionRX Limited (NYSEAMERICAN:VNRX) have been given a consensus recommendation of “Moderate Buy” by the six analysts that are covering the company, Marketbeat reports. Four analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $46.6667.

Several brokerages recently issued reports on VNRX. HC Wainwright reduced their price objective on VolitionRX from $30.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. Citigroup cut shares of VolitionRX to a “hold” rating in a report on Monday, April 20th. Benchmark restated a “hold” rating on shares of VolitionRX in a research report on Tuesday. Finally, D. Boral Capital reaffirmed a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th.

Hedge Funds Weigh In On VolitionRX

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in VolitionRX during the third quarter valued at about $28,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of VolitionRX in the second quarter worth approximately $52,000. Jane Street Group LLC acquired a new stake in shares of VolitionRX during the fourth quarter valued at approximately $28,000. Squarepoint Ops LLC acquired a new stake in shares of VolitionRX during the fourth quarter valued at approximately $34,000. Finally, Citadel Advisors LLC lifted its position in shares of VolitionRX by 70.1% in the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after acquiring an additional 135,775 shares in the last quarter. 8.09% of the stock is owned by institutional investors.

VolitionRX Stock Down 11.6%

Shares of NYSEAMERICAN VNRX traded down $0.31 during trading on Tuesday, reaching $2.36. 250,291 shares of the stock were exchanged, compared to its average volume of 290,090. The company has a market capitalization of $19.66 million, a price-to-earnings ratio of -0.58 and a beta of 1.04. The business’s 50-day moving average price is $3.06 and its 200 day moving average price is $4.50. VolitionRX has a twelve month low of $1.91 and a twelve month high of $18.80.

VolitionRX (NYSEAMERICAN:VNRX) last issued its quarterly earnings data on Thursday, May 14th. The medical research company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.27). The business had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.52 million. As a group, sell-side analysts expect that VolitionRX will post -2.4 earnings per share for the current fiscal year.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.